![Atossa Therapeutics Inc](/common/images/company/N_ATOS.png)
Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other brea... Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. Show more
SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced the appointment of Heather Rees as the Company’s new Chief...
SEATTLE, June 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced protocol changes in the previously initiated study to evaluate...
SEATTLE, June 17, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its expected upcoming inclusion in the Russell 3000® Index...
SEATTLE, June 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the Company will present at the Sidoti Small-Cap Investor...
SEATTLE, May 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced support for a new Phase 2 study designed to validate an...
SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the last patient in the Company’s Karisma-Endoxifen clinical...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.13 | 12.5 | 1.04 | 1.3 | 1.035 | 4687082 | 1.16953977 | CS |
4 | -0.17 | -12.6865671642 | 1.34 | 1.34 | 1.02 | 1784245 | 1.17201872 | CS |
12 | -0.62 | -34.6368715084 | 1.79 | 1.84 | 1.02 | 1482013 | 1.38531872 | CS |
26 | 0.2525 | 27.5204359673 | 0.9175 | 2.31 | 0.7744 | 1401401 | 1.47056629 | CS |
52 | -0.08 | -6.4 | 1.25 | 2.31 | 0.62 | 943333 | 1.32758692 | CS |
156 | -4.06 | -77.6290630975 | 5.23 | 7.15 | 0.5 | 1984790 | 2.67133027 | CS |
260 | -1.21 | -50.8403361345 | 2.38 | 9.8 | 0.5 | 3527900 | 3.15820563 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.